US Bioservices now dispenses TAVALISSE
June 18, 2018
The U.S. Food and Drug Administration has recently approved TAVALISSE (fostamatinib) for the treatment of chronic/persistent immune thrombocytopenic purpura (ITP).
.png?bc=ffffff&h=60&la=en&w=250&hash=D4E558BE41F5D9E7E7CC458758B16488B3D292F9){kind=logo}
The U.S. Food and Drug Administration has recently approved TAVALISSE (fostamatinib) for the treatment of chronic/persistent immune thrombocytopenic purpura (ITP).